Phenotypic features and genetic characterization of male breast cancer families: Identification of two recurrent BRCA2 mutations in north-east of Italy

Gian Maria Miolo, Lara Della Puppa, Manuela Santarosa, Celia De Giacomi, Andrea Veronesi, Ettore Bidoli, Maria Grazia Tibiletti, Alessandra Viel, Riccardo Dolcetti

Research output: Contribution to journalArticle

Abstract

Background: Breast cancer in men is an infrequent occurrence, accounting for ∼1% of all breast tumors with an incidence of about 1:100,000. The relative rarity of male breast cancer (MBC) limits our understanding of the epidemiologic, genetic and clinical features of this tumor. Methods: From 1997 to 2003, 10 MBC patients were referred to our Institute for genetic counselling and BRCA1/2 testing. Here we report on the genetic and phenotypic characterization of 10 families with MBC from the North East of Italy. In particular, we wished to assess the occurrence of specific cancer types in relatives of MBC probands in families with and without BRCA2 predisposing mutations. Moreover, families with recurrent BRCA2 mutations were also characterized by haplotype analysis using 5 BRCA2-linked dinucleotide repeat markers and 8 intragenic BRCA2 polymorphisms. Results: Two pathogenic mutations in the BRCA2 gene were observed: the 9106C>T (Q2960X) and the IVS16-2A>G (splicing) mutations, each in 2 cases. A BRCA1 mutation of uncertain significance 4590C>G (P1491A) was also observed. In families with BRCA2 mutations, female breast cancer was more frequent in the first and second-degree relatives compared to the families with wild type BRCA1/2 (31.9% vs. 8.0% p = 0.001). Reconstruction of the chromosome phasing in three families and the analysis of three isolated cases with the IVS16-2A>G BRCA2 mutation identified the same haplotype associated with MBC, supporting the possibility that this founder mutation previously detected in Slovenian families is also present in the North East of our Country. Moreover, analysis of one family with the 9106C>T BRCA2 mutation allowed the identification of common haplotypes for both microsatellite and intragenic polymorphisms segregating with the mutation. Three isolated cases with the same mutation shared the same intragenic polymorphisms and three 5′ microsatellite markers, but showed a different haplotype for 3′ markers, which were common to all three cases. Conclusion: The 9106C>T and the IVS16-2A>G mutations constitute recurrent BRCA2 mutations in MBC cases from the North-East of Italy and may be associated with a founder effect. Knowledge of these two recurrent BRCA2 mutations predisposing to MBC may facilitate the analyses aimed at the identification of mutation carriers in our geographic area.

Original languageEnglish
Article number156
JournalBMC Cancer
Volume6
DOIs
Publication statusPublished - Jun 9 2006

Fingerprint

Male Breast Neoplasms
Italy
Mutation
Haplotypes
Breast Neoplasms
Microsatellite Repeats
BRCA2 Gene
Dinucleotide Repeats
Founder Effect
Genetic Counseling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phenotypic features and genetic characterization of male breast cancer families : Identification of two recurrent BRCA2 mutations in north-east of Italy. / Miolo, Gian Maria; Della Puppa, Lara; Santarosa, Manuela; De Giacomi, Celia; Veronesi, Andrea; Bidoli, Ettore; Tibiletti, Maria Grazia; Viel, Alessandra; Dolcetti, Riccardo.

In: BMC Cancer, Vol. 6, 156, 09.06.2006.

Research output: Contribution to journalArticle

Miolo, Gian Maria ; Della Puppa, Lara ; Santarosa, Manuela ; De Giacomi, Celia ; Veronesi, Andrea ; Bidoli, Ettore ; Tibiletti, Maria Grazia ; Viel, Alessandra ; Dolcetti, Riccardo. / Phenotypic features and genetic characterization of male breast cancer families : Identification of two recurrent BRCA2 mutations in north-east of Italy. In: BMC Cancer. 2006 ; Vol. 6.
@article{ffed4200b4854da9b701c5af0f544f8e,
title = "Phenotypic features and genetic characterization of male breast cancer families: Identification of two recurrent BRCA2 mutations in north-east of Italy",
abstract = "Background: Breast cancer in men is an infrequent occurrence, accounting for ∼1{\%} of all breast tumors with an incidence of about 1:100,000. The relative rarity of male breast cancer (MBC) limits our understanding of the epidemiologic, genetic and clinical features of this tumor. Methods: From 1997 to 2003, 10 MBC patients were referred to our Institute for genetic counselling and BRCA1/2 testing. Here we report on the genetic and phenotypic characterization of 10 families with MBC from the North East of Italy. In particular, we wished to assess the occurrence of specific cancer types in relatives of MBC probands in families with and without BRCA2 predisposing mutations. Moreover, families with recurrent BRCA2 mutations were also characterized by haplotype analysis using 5 BRCA2-linked dinucleotide repeat markers and 8 intragenic BRCA2 polymorphisms. Results: Two pathogenic mutations in the BRCA2 gene were observed: the 9106C>T (Q2960X) and the IVS16-2A>G (splicing) mutations, each in 2 cases. A BRCA1 mutation of uncertain significance 4590C>G (P1491A) was also observed. In families with BRCA2 mutations, female breast cancer was more frequent in the first and second-degree relatives compared to the families with wild type BRCA1/2 (31.9{\%} vs. 8.0{\%} p = 0.001). Reconstruction of the chromosome phasing in three families and the analysis of three isolated cases with the IVS16-2A>G BRCA2 mutation identified the same haplotype associated with MBC, supporting the possibility that this founder mutation previously detected in Slovenian families is also present in the North East of our Country. Moreover, analysis of one family with the 9106C>T BRCA2 mutation allowed the identification of common haplotypes for both microsatellite and intragenic polymorphisms segregating with the mutation. Three isolated cases with the same mutation shared the same intragenic polymorphisms and three 5′ microsatellite markers, but showed a different haplotype for 3′ markers, which were common to all three cases. Conclusion: The 9106C>T and the IVS16-2A>G mutations constitute recurrent BRCA2 mutations in MBC cases from the North-East of Italy and may be associated with a founder effect. Knowledge of these two recurrent BRCA2 mutations predisposing to MBC may facilitate the analyses aimed at the identification of mutation carriers in our geographic area.",
author = "Miolo, {Gian Maria} and {Della Puppa}, Lara and Manuela Santarosa and {De Giacomi}, Celia and Andrea Veronesi and Ettore Bidoli and Tibiletti, {Maria Grazia} and Alessandra Viel and Riccardo Dolcetti",
year = "2006",
month = "6",
day = "9",
doi = "10.1186/1471-2407-6-156",
language = "English",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Phenotypic features and genetic characterization of male breast cancer families

T2 - Identification of two recurrent BRCA2 mutations in north-east of Italy

AU - Miolo, Gian Maria

AU - Della Puppa, Lara

AU - Santarosa, Manuela

AU - De Giacomi, Celia

AU - Veronesi, Andrea

AU - Bidoli, Ettore

AU - Tibiletti, Maria Grazia

AU - Viel, Alessandra

AU - Dolcetti, Riccardo

PY - 2006/6/9

Y1 - 2006/6/9

N2 - Background: Breast cancer in men is an infrequent occurrence, accounting for ∼1% of all breast tumors with an incidence of about 1:100,000. The relative rarity of male breast cancer (MBC) limits our understanding of the epidemiologic, genetic and clinical features of this tumor. Methods: From 1997 to 2003, 10 MBC patients were referred to our Institute for genetic counselling and BRCA1/2 testing. Here we report on the genetic and phenotypic characterization of 10 families with MBC from the North East of Italy. In particular, we wished to assess the occurrence of specific cancer types in relatives of MBC probands in families with and without BRCA2 predisposing mutations. Moreover, families with recurrent BRCA2 mutations were also characterized by haplotype analysis using 5 BRCA2-linked dinucleotide repeat markers and 8 intragenic BRCA2 polymorphisms. Results: Two pathogenic mutations in the BRCA2 gene were observed: the 9106C>T (Q2960X) and the IVS16-2A>G (splicing) mutations, each in 2 cases. A BRCA1 mutation of uncertain significance 4590C>G (P1491A) was also observed. In families with BRCA2 mutations, female breast cancer was more frequent in the first and second-degree relatives compared to the families with wild type BRCA1/2 (31.9% vs. 8.0% p = 0.001). Reconstruction of the chromosome phasing in three families and the analysis of three isolated cases with the IVS16-2A>G BRCA2 mutation identified the same haplotype associated with MBC, supporting the possibility that this founder mutation previously detected in Slovenian families is also present in the North East of our Country. Moreover, analysis of one family with the 9106C>T BRCA2 mutation allowed the identification of common haplotypes for both microsatellite and intragenic polymorphisms segregating with the mutation. Three isolated cases with the same mutation shared the same intragenic polymorphisms and three 5′ microsatellite markers, but showed a different haplotype for 3′ markers, which were common to all three cases. Conclusion: The 9106C>T and the IVS16-2A>G mutations constitute recurrent BRCA2 mutations in MBC cases from the North-East of Italy and may be associated with a founder effect. Knowledge of these two recurrent BRCA2 mutations predisposing to MBC may facilitate the analyses aimed at the identification of mutation carriers in our geographic area.

AB - Background: Breast cancer in men is an infrequent occurrence, accounting for ∼1% of all breast tumors with an incidence of about 1:100,000. The relative rarity of male breast cancer (MBC) limits our understanding of the epidemiologic, genetic and clinical features of this tumor. Methods: From 1997 to 2003, 10 MBC patients were referred to our Institute for genetic counselling and BRCA1/2 testing. Here we report on the genetic and phenotypic characterization of 10 families with MBC from the North East of Italy. In particular, we wished to assess the occurrence of specific cancer types in relatives of MBC probands in families with and without BRCA2 predisposing mutations. Moreover, families with recurrent BRCA2 mutations were also characterized by haplotype analysis using 5 BRCA2-linked dinucleotide repeat markers and 8 intragenic BRCA2 polymorphisms. Results: Two pathogenic mutations in the BRCA2 gene were observed: the 9106C>T (Q2960X) and the IVS16-2A>G (splicing) mutations, each in 2 cases. A BRCA1 mutation of uncertain significance 4590C>G (P1491A) was also observed. In families with BRCA2 mutations, female breast cancer was more frequent in the first and second-degree relatives compared to the families with wild type BRCA1/2 (31.9% vs. 8.0% p = 0.001). Reconstruction of the chromosome phasing in three families and the analysis of three isolated cases with the IVS16-2A>G BRCA2 mutation identified the same haplotype associated with MBC, supporting the possibility that this founder mutation previously detected in Slovenian families is also present in the North East of our Country. Moreover, analysis of one family with the 9106C>T BRCA2 mutation allowed the identification of common haplotypes for both microsatellite and intragenic polymorphisms segregating with the mutation. Three isolated cases with the same mutation shared the same intragenic polymorphisms and three 5′ microsatellite markers, but showed a different haplotype for 3′ markers, which were common to all three cases. Conclusion: The 9106C>T and the IVS16-2A>G mutations constitute recurrent BRCA2 mutations in MBC cases from the North-East of Italy and may be associated with a founder effect. Knowledge of these two recurrent BRCA2 mutations predisposing to MBC may facilitate the analyses aimed at the identification of mutation carriers in our geographic area.

UR - http://www.scopus.com/inward/record.url?scp=33749413268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749413268&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-156

DO - 10.1186/1471-2407-6-156

M3 - Article

C2 - 16764716

AN - SCOPUS:33749413268

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 156

ER -